Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Hironari Kato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1120-292X; OpenAlex author ID A5064565558. Sources: OpenAlex.

Their work

Papers
30 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 4 papers

Papers 30

  1. Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer. First author DOI 10.1111/den.14815↗
  2. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  3. Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Co-author DOI 10.7759/cureus.79001↗
  4. Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Co-author DOI 10.7759/cureus.c365↗
  5. Association of screening tool scores with overall survival in older patients with unresectable gastrointestinal or biliary pancreatic cancer: A retrospective s… Co-author DOI 10.1016/j.jgo.2024.101714↗
  6. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  7. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. Co-author DOI 10.1016/j.pan.2023.10.018↗
  8. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer. Last author DOI 10.18926/amo/65974↗
  9. Effectiveness of an Oral Elemental Diet for Patients With Unresectable Pancreatic Cancer: a Prospective Cohort Study Co-author DOI 10.21203/rs.3.rs-1244457/v1↗
  10. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. First author DOI 10.1080/15384047.2021.1980312↗
  11. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. First author DOI 10.1007/s10620-019-06006-6↗
  12. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Co-author DOI 10.1007/s00535-019-01586-6↗
  13. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2019.1638685↗
  14. Diagnostic Ability of Convex-Arrayed Endoscopic Ultrasonography for Major Vascular Invasion in Pancreatic Cancer. Co-author DOI 10.5946/ce.2018.163↗
  15. Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients. Co-author DOI 10.1007/s00795-018-0197-8↗
  16. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cance… First author DOI 10.1186/s12876-018-0886-8↗
  17. Preoperative Detection of Tumor Seeding after Endoscopic Ultrasonography-guided Fine Needle Aspiration for Pancreatic Cancer. First author DOI 10.2169/internalmedicine.0321-17↗
  18. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Co-author DOI 10.1016/j.pan.2016.12.011↗
  19. Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer. Co-author DOI 10.1038/cgt.2016.31↗
  20. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mon… Co-author DOI 10.1111/jgh.13259↗
  21. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29364↗
  22. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine. Co-author DOI 10.1097/mpa.0000000000000321↗
  23. Serum anti-60S ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer. Co-author DOI 10.1159/000371545↗
  24. Corrigendum to “Loss of runt‐related transcription factor 3 induces gemcitabine resistance in pancreatic cancer” [Mol. Oncol. 7 (2013) 840–849] Co-author DOI 10.1016/j.molonc.2014.03.007↗
  25. Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. Co-author DOI 10.1111/jgh.12501↗
  26. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-012-0732-7↗
  27. Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2013.04.004↗
  28. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.009↗
  29. A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensit… Co-author DOI 10.1007/s10147-011-0237-z↗
  30. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Co-author DOI 10.1159/000330384↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuyuki Matsumoto · 15 shared papers, 2011–2025 · strength 2.11
  2. Shigeru Horiguchi · 18 shared papers, 2013–2025 · strength 1.94
  3. Motoyuki Otsuka · 6 shared papers, 2023–2025 · strength 1.36
  4. Koichiro Tsutsumi · 11 shared papers, 2011–2025 · strength 1.05
  5. Hiroyuki Okada · 10 shared papers, 2012–2024 · strength 0.94
  6. Daisuke Uchida · 10 shared papers, 2014–2023 · strength 0.79
  7. Kazuhiro Nouso · 13 shared papers, 2012–2021 · strength 0.69
  8. Ryosuke Sato · 3 shared papers, 2022–2025 · strength 0.64
  9. Yuki Fujii · 4 shared papers, 2019–2025 · strength 0.60
  10. Hiroyuki Terasawa · 4 shared papers, 2019–2023 · strength 0.52
  11. Shinichiro Muro · 6 shared papers, 2015–2021 · strength 0.49
  12. Hideaki Kinugasa · 6 shared papers, 2015–2021 · strength 0.43
  13. Kazuhide Yamamoto · 11 shared papers, 2011–2016 · strength 0.41
  14. Yuzo Umeda · 3 shared papers, 2019–2025 · strength 0.38
  15. Ryuichi Yoshida · 3 shared papers, 2019–2025 · strength 0.38
  16. Soichiro Ako · 4 shared papers, 2017–2021 · strength 0.35
  17. Kazuya Yasui · 1 shared paper, 2025 · strength 0.19
  18. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19
  19. Yasuo Nagai · 1 shared paper, 2025 · strength 0.19
  20. Kazuhiro Yoshida · 1 shared paper, 2025 · strength 0.19
  21. Kosei Takagi · 1 shared paper, 2025 · strength 0.19
  22. Takeyoshi Nishiyama · 1 shared paper, 2025 · strength 0.19
  23. Toshiyoshi Fujiwara · 1 shared paper, 2025 · strength 0.19
  24. Hiroyuki Okada · 2 shared papers, 2018–2021 · strength 0.18
  25. Shoko Inoo · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.